The naive question, two years into the pandemic: everyone says “mRNA,” but what is it actually doing inside you? The short version, and Moderna's own annual report supports the framing, is that an mRNA medicine hands your cells a temporary recipe and lets them build the protein themselves.
In its Form 10-K filed February 25, 2022, Moderna describes its COVID-19 vaccine (mRNA-1273) as requiring a single mRNA sequence for inclusion in an intramuscular mRNA medicine. That phrasing is the whole concept in miniature: the drug is a sequence — a string of genetic instructions — packaged so a muscle cell can read it.
Think of it like emailing a blueprint instead of shipping the finished part. Older vaccines often deliver the actual protein or a weakened pathogen. An mRNA vaccine instead delivers the instructions for a single protein (for COVID, the spike), your cells make that protein briefly, and your immune system learns to recognize it. The instructions then degrade. Nothing changes your DNA — mRNA does not enter the cell's nucleus where DNA lives.
Here's why the platform idea follows naturally from the filing. If the medicine is essentially a sequence, then making a different medicine can mean swapping the sequence while keeping much of the same manufacturing and delivery system. That is why a company can describe one COVID product and, in the same document, a pipeline of other mRNA programs — the underlying modality is reusable.
Keep the “so what” honest. As of this 2022 filing, the COVID-19 vaccine is the proven application. The reusability of the platform is a real engineering advantage, but each new sequence still has to clear its own trials. The modality is elegant; the clinical work is not automatic.
The EdgarBeast evidence index, which surfaces and normalizes SEC filings, lets you read a company explain its own technology in its own regulated words. Moderna's 2021 10-K describes mRNA as a single sequence delivered intramuscularly — a recipe, not a finished protein. That is the modality, in plain terms.